Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Docetaxel by Zhuhai Beihai Biotech for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Docetaxel is under clinical development by Zhuhai Beihai Biotech and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According...
Docetaxel by Zhuhai Beihai Biotech for Non-Small Cell Lung Cancer: Likelihood of Approval
Docetaxel is under clinical development by Zhuhai Beihai Biotech and currently in Pre-Registration for Non-Small Cell Lung Cancer. According to...
Docetaxel by Zhuhai Beihai Biotech for Gastric Cancer: Likelihood of Approval
Docetaxel is under clinical development by Zhuhai Beihai Biotech and currently in Pre-Registration for Gastric Cancer. According to GlobalData, Pre-Registration...
Docetaxel by Zhuhai Beihai Biotech for Prostate Cancer: Likelihood of Approval
Docetaxel is under clinical development by Zhuhai Beihai Biotech and currently in Pre-Registration for Prostate Cancer. According to GlobalData, Pre-Registration...
Docetaxel by Zhuhai Beihai Biotech for Breast Cancer: Likelihood of Approval
Docetaxel is under clinical development by Zhuhai Beihai Biotech and currently in Pre-Registration for Breast Cancer. According to GlobalData, Pre-Registration...
Docetaxel by Nanology for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval
Docetaxel is under clinical development by Nanology and currently in Phase II for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial...
Docetaxel by Plus Therapeutics for Cervical Cancer: Likelihood of Approval
Docetaxel is under clinical development by Plus Therapeutics and currently in Phase I for Cervical Cancer. According to GlobalData, Phase...
Docetaxel by Starpharma for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Docetaxel is under clinical development by Starpharma and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData,...
Docetaxel by Nanology for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval
Docetaxel is under clinical development by Nanology and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell Carcinoma). According...
Docetaxel by Starpharma for Pancreatic Cancer: Likelihood of Approval
Docetaxel is under clinical development by Starpharma and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II...
Docetaxel by Nanology for Muscle Invasive Bladder Cancer (MIBC): Likelihood of Approval
Docetaxel is under clinical development by Nanology and currently in Phase II for Muscle Invasive Bladder Cancer (MIBC). According to...
Docetaxel by Starpharma for Ocular Melanoma: Likelihood of Approval
Docetaxel is under clinical development by Starpharma and currently in Phase II for Ocular Melanoma. According to GlobalData, Phase II...
Docetaxel by Starpharma for Esophageal Cancer: Likelihood of Approval
Docetaxel is under clinical development by Starpharma and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase II...
Docetaxel by Starpharma for Solid Tumor: Likelihood of Approval
Docetaxel is under clinical development by Starpharma and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...
Docetaxel by Starpharma for Sarcomas: Likelihood of Approval
Docetaxel is under clinical development by Starpharma and currently in Phase II for Sarcomas. According to GlobalData, Phase II drugs...
Docetaxel by Starpharma for Gastric Cancer: Likelihood of Approval
Docetaxel is under clinical development by Starpharma and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II...
Docetaxel by Zhuhai Beihai Biotech for Solid Tumor: Likelihood of Approval
Docetaxel is under clinical development by Zhuhai Beihai Biotech and currently in Phase III for Solid Tumor. According to GlobalData,...
Docetaxel by Samyang Biopharmaceuticals for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Docetaxel is under clinical development by Samyang Biopharmaceuticals and currently in Phase III for Human Epidermal Growth Factor Receptor 2...
Docetaxel by Starpharma for Non-Small Cell Lung Cancer: Likelihood of Approval
Docetaxel is under clinical development by Starpharma and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...